N Eisemann1, L Jansen2, F A Castro2, T Chen3, A Eberle4, A Nennecke5, S R Zeissig6, H Brenner2,7,8, A Katalinic1,9. 1. Institute of Social Medicine and Epidemiology, University of Lübeck, Ratzeburger Allee 160, 23562, Lübeck, Germany. 2. Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), 69120, Heidelberg, Germany. 3. Division of Molecular Genetic Epidemiology (C050), German Cancer Research Center (DKFZ), 69120, Heidelberg, Germany. 4. Cancer Registry of Bremen, Achterstraße 30, 28359, Bremen, Germany. 5. Cancer Registry of Hamburg, Billstraße 80, 20539, Hamburg, Germany. 6. Cancer Registry of Rhineland-Palatinate, Obere Zahlbacher Straße 69, 55131, Mainz, Germany. 7. Division of Preventive Oncology, German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT), INF 460, 69120, Heidelberg, Germany. 8. German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), 69120, Heidelberg, Germany. 9. Institute of Cancer Epidemiology, University of Lübeck, Ratzeburger Allee 160, 23562, Lübeck, Germany.
Abstract
BACKGROUND: Nonmelanoma skin cancer (NMSC) is the most common cancer in Germany, but detailed information on survival is lacking. OBJECTIVES: To provide survival estimates for female and male patients with basal cell carcinoma (BCC), squamous cell carcinoma (SCC), sarcoma, adenocarcinoma and Merkel cell carcinoma. Further subgroup analyses were carried out by age, tumour stage and body site. METHODS: In total 459 640 patients diagnosed with NMSC in 1997-2011 were included from population-based cancer registers, covering a population of 33 million inhabitants. Age-standardized absolute and relative 5-year and 10-year survival were calculated using period analysis. RESULTS: The absolute and relative 5-year survival were 87·1% and 102·9% for BCC, 77·6% and 93·6% for SCC, 82·1% and 96·0% for sarcoma, 71·4% and 85·7% for adenocarcinoma and 60·0% and 70·7% for Merkel cell carcinoma, respectively. Higher age, female sex and advanced stage were associated with lower survival. CONCLUSIONS: A comprehensive overview of NMSC survival in Germany is provided. The differences between the NMSC subtypes require a more differentiated consideration of patient survival. The survival advantage of patients with BCC may be related to health-promoting factors related to the BCC diagnosis, such as changes to a healthier lifestyle.
BACKGROUND:Nonmelanoma skin cancer (NMSC) is the most common cancer in Germany, but detailed information on survival is lacking. OBJECTIVES: To provide survival estimates for female and male patients with basal cell carcinoma (BCC), squamous cell carcinoma (SCC), sarcoma, adenocarcinoma and Merkel cell carcinoma. Further subgroup analyses were carried out by age, tumour stage and body site. METHODS: In total 459 640 patients diagnosed with NMSC in 1997-2011 were included from population-based cancer registers, covering a population of 33 million inhabitants. Age-standardized absolute and relative 5-year and 10-year survival were calculated using period analysis. RESULTS: The absolute and relative 5-year survival were 87·1% and 102·9% for BCC, 77·6% and 93·6% for SCC, 82·1% and 96·0% for sarcoma, 71·4% and 85·7% for adenocarcinoma and 60·0% and 70·7% for Merkel cell carcinoma, respectively. Higher age, female sex and advanced stage were associated with lower survival. CONCLUSIONS: A comprehensive overview of NMSC survival in Germany is provided. The differences between the NMSC subtypes require a more differentiated consideration of patient survival. The survival advantage of patients with BCC may be related to health-promoting factors related to the BCC diagnosis, such as changes to a healthier lifestyle.
Authors: Jürgen C Becker; Andreas Stang; Axel Zur Hausen; Nicole Fischer; James A DeCaprio; Richard W Tothill; Rikke Lyngaa; Ulla Kring Hansen; Cathrin Ritter; Paul Nghiem; Christopher K Bichakjian; Selma Ugurel; David Schrama Journal: Cancer Immunol Immunother Date: 2017-11-30 Impact factor: 6.968
Authors: Virginia Barton; Kent Armeson; Shalaka Hampras; Laura K Ferris; Kala Visvanathan; Dana Rollison; Anthony J Alberg Journal: Arch Dermatol Res Date: 2017-03-11 Impact factor: 3.017
Authors: Marita Yaghi; Paul Benedetto; John Greskovich; Roger Haber; Barbara Dominguez; Hong Liang; Zeina Nahleh; Rafael Arteta-Bulos Journal: JAAD Int Date: 2022-06-17
Authors: Zoë C Venables; Philippe Autier; Tamar Nijsten; Kwok F Wong; Sinéad M Langan; Brian Rous; John Broggio; Catherine Harwood; Katherine Henson; Charlotte M Proby; Jem Rashbass; Irene M Leigh Journal: JAMA Dermatol Date: 2019-03-01 Impact factor: 10.282
Authors: Kelly G Paulson; Song Youn Park; Natalie A Vandeven; Kristina Lachance; Hannah Thomas; Aude G Chapuis; Kelly L Harms; John A Thompson; Shailender Bhatia; Andreas Stang; Paul Nghiem Journal: J Am Acad Dermatol Date: 2017-11-02 Impact factor: 11.527
Authors: Z C Venables; T Nijsten; K F Wong; P Autier; J Broggio; A Deas; C A Harwood; L M Hollestein; S M Langan; E Morgan; C M Proby; J Rashbass; I M Leigh Journal: Br J Dermatol Date: 2019-05-06 Impact factor: 9.302